Mercado de descubrimiento de fármacos de moléculas pequeñas: mapeo competitivo y perspectivas estratégicas para 2031

  • Report Code : TIPRE00004774
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 173
Buy Now

El mercado de descubrimiento de fármacos de moléculas pequeñas se valoró en 24.976,14 millones de dólares en 2019 y se prevé que alcance los 50.823,06 millones de dólares en 2027; se espera que crezca a una tasa compuesta anual del 9,5 % entre 2020 y 2027.

Los medicamentos de moléculas pequeñas se utilizan en la administración dirigida de medicamentos en la que las moléculas pequeñas pasan a través de la membrana celular. y actúa sobre el orgánulo celular o proteína específica. Los fármacos de moléculas pequeñas pueden ingresar a las células fácilmente debido a su bajo peso molecular. Estas moléculas son mejores que los anticuerpos monoclonales y otros fármacos de moléculas grandes debido a su tamaño, fácil convertibilidad a la forma oral y rentabilidad. Se espera que el mercado de descubrimiento de fármacos de moléculas pequeñas experimente un enorme crecimiento debido a la creciente aprobación de fármacos de moléculas pequeñas, la creciente demanda de I+D por parte de organizaciones contratadas y la creciente adopción de moléculas pequeñas en tratamientos de enfermedades crónicas. Sin embargo, se espera que el alto costo de desarrollo de medicamentos restrinja el crecimiento del mercado durante el período de pronóstico.

regiones lucrativas para el mercado de descubrimiento de fármacos de moléculas pequeñas< br />

Perspectivas del mercado

Adopción creciente de moléculas pequeñas en tratamientos de enfermedades crónicas

< p>Según los Centros para el Control de Enfermedades (CDC), 6 de cada 10 adultos sufren de una condición crónica, como enfermedades cardíacas, diabetes, cáncer, enfermedades renales, enfermedades pulmonares o accidentes cerebrovasculares en los EE. UU., lo que cuesta 3,5 billones de dólares a la economía de los EE.UU. anualmente para el tratamiento de estas enfermedades crónicas. Las enfermedades crónicas son la causa más importante de muerte en todo el mundo y su número aumenta cada año. Por ejemplo, según los CDC, más de 1,6 millones de personas son diagnosticadas con cáncer cada año en los EE. UU.

Se espera que los medicamentos de molécula pequeña proporcionen opciones de tratamiento efectivas para enfermedades crónicas debido a su tamaño y capacidad para cruzar las barreras celulares. También se pueden diseñar para cruzar la barrera hematoencefálica y atacar enfermedades neurológicas. Se espera que las moléculas pequeñas desempeñen un papel fundamental en la reducción de la carga de enfermedades crónicas. En los próximos años, se espera que las moléculas pequeñas ayuden a formular tratamientos más eficientes y eficaces para las enfermedades crónicas.

Perspectivas basadas en áreas terapéuticas

Según el área terapéutica, el mercado de descubrimiento de fármacos de moléculas pequeñas está segmentado en oncología, sistema nervioso central, cardiovascular, respiratorio, ortopedia, inmunología, enfermedades raras y otras áreas terapéuticas. El segmento de oncología tuvo la mayor participación del mercado en 2019 debido a las crecientes aprobaciones de medicamentos de molécula pequeña y la creciente cartera de terapias contra el cáncer. Además, el aumento de la inversión en oncología está impulsando aún más el crecimiento del segmento. Por ejemplo, en diciembre de 2019, Zentalis Pharmaceuticals, una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias novedosas de moléculas pequeñas clínicamente diferenciadas que se dirigen a vías fundamentales del cáncer, completó una financiación de Serie C de 85 millones de dólares. Sin embargo, se espera que el segmento de enfermedades raras registre una CAGR más alta en el mercado durante el período de pronóstico.

Mercado global de descubrimiento de fármacos de molécula pequeña, por área terapéutica: 2019 y 2027

Información basada en procesos/fases

Basado en procesos/fases, el mercado de descubrimiento de fármacos de moléculas pequeñas se segmenta en descubrimiento de objetivos, validación de objetivos, generación y refinamiento de leads y desarrollo preclínico. El segmento de generación y refinamiento de leads tuvo la mayor participación en el mercado mundial de descubrimiento de fármacos de moléculas pequeñas en 2019, debido al aumento de la inversión en el descubrimiento de fármacos y a la creciente demanda de terapias rentables. Además, el descubrimiento del objetivo implica la identificación de objetivos modificadores de la enfermedad, lo que actúa como uno de los pasos esenciales en el proceso de descubrimiento de fármacos. Sin embargo, se prevé que el descubrimiento objetivo registre la CAGR más alta durante el período de pronóstico.

Información estratégica

Las colaboraciones y la estrategia de expansión son comúnmente adoptadas por empresas expandir su presencia en todo el mundo y satisfacer la creciente demanda para ampliar su cartera de productos.

Los actores del mercado que operan en el mercado de descubrimiento de fármacos de moléculas pequeñas adoptaron la estrategia de producto innovación para satisfacer la demanda cambiante de los clientes en todo el mundo, lo que también permite a los actores mantener su marca a nivel mundial.

Mercado de descubrimiento de fármacos de moléculas pequeñas: Por Área Terapéutica

  • Oncología
  • Sistema Nervioso Central
  • Cardiovascular
  • Respiratoria
  • Ortopedia
  • Inmunología
  • Enfermedades raras
  • Otras áreas terapéuticas

Mercado de descubrimiento de fármacos de moléculas pequeñas – ndash; Por proceso/fase

  • Descubrimiento de objetivos
  • Validación de objetivos
  • Generación y refinamiento de leads
  • Desarrollo preclínico
  • < /ul>

    Mercado de descubrimiento de fármacos de moléculas pequeñas– Por geografía

    • América del Norte
      • Estados Unidos
      • Canadá
      • México
    • < li>Europa
      • Francia
      • Alemania
      • Italia
      • Reino Unido
      • España
      • Resto de Europa
    • Asia Pacífico(APAC)
      • China
      • India
      • Corea del Sur
      • Japón
      • Australia
      • Resto de APAC
    • Oriente Medio y África (MEA)
      • Sudáfrica
      • Arabia Saudita
      • EAU
      • Resto de MEA
    • América del Sur (SAM)< ul>
    • Brasil
    • Argentina
    • Resto de SAM
< h3>Perfiles de la empresa
  • Johnson and Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Allergan Plc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • MERCK KGaA
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Gilead Sciences, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is small molecule drug discovery market?

Small molecules drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form and cost affectivity. The discovery of novel small molecule entities that are capable of specific interactions represents a significant challenge in the early stages of drug discovery. When the biological target is well defined and understood, the rational design of small molecule ligands is possible. In the recent years, the small molecules have witnessed significant attention over biologics, as there is an increasing demand for these drugs.

What are the driving factors for the small molecule drug discovery market across the globe?

The factors that are driving growth of the market are increasing approval of small molecule drugs, growing demand for R&D from contract organizations, and rising adoption of small molecules in chronic disease treatments propel the growth of the market.

Who are the major players in the small molecule drug discovery market?

The small molecule drug discovery market majorly consists of the players such as Pfizer Inc., Bristol-Myers Squibb Company, Merck KGaA, GlaxoSmithKline Plc, AstraZeneca, Johnson & Johnson Services, Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Boehringer Ingelheim International GmbH, and Allergan Plc.

The List of Companies - Small Molecule Drug Discovery Market

  1. Johnson and Johnson Services, Inc.
  2. Teva Pharmaceutical Industries Ltd
  3. Boehringer Ingelheim International GmbH
  4. Allergan Plc.
  5. Pfizer Inc.
  6. Bristol-Myers Squibb Company
  7. MERCK KGaA
  8. GlaxoSmithKline plc.
  9. AstraZeneca
  10. Gilead Sciences, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports